Companies /Healthcare

Boston Scientific Corp

NYSE: BSX Medical Devices
$48.30
â–² $1.46 (+3.12%) today
Markets closed · 7:22pm ET

Q1 2025 Earnings

Reported Apr 23, 2025, 6:34am ET · SEC source
$0.75
Beat +11.94%
EPS · est. $0.67
$4.7B
Beat +1.98%
Revenue · est. $4.6B
−2.5%
Trailing market
BSX vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+3%Apr 23Apr 24report 6:34am ETearnings+1.1%+3.0%
0+3%Apr 23Apr 24earnings+1.1%+3.0%
BSX +3.0%S&P 500 +1.1%
0+3%Apr 23Apr 24report 6:34am ETearnings+2.0%+3.0%
0+3%Apr 23Apr 24earnings+2.0%+3.0%
BSX +3.0%NASDAQ +2.0%
−6%−3%0+3%Apr 22Apr 30report 6:34am ETearnings+3.3%+2.3%
−6%−3%0+3%Apr 22Apr 30earnings+3.3%+2.3%
BSX +2.3%S&P 500 +3.3%
−4%0+4%Apr 22Apr 30report 6:34am ETearnings+5.0%+2.3%
−4%0+4%Apr 22Apr 30earnings+5.0%+2.3%
BSX +2.3%NASDAQ +5.0%
+4.07%
Day of report
+2.24%
Next session
+3.99%
One week
+5.64%
30 days

S&P 500 over the same 30 days: +8.16%.

Did BSX Beat Earnings? Q1 2025 Results

Boston Scientific kicked off 2025 with a standout first quarter, posting adjusted EPS of $0.75 against a consensus estimate of $0.67, a beat of 11.52%, while revenue of $4.66 billion topped the $4.57 billion estimate by 1.98% and grew 20.9% year over year, exceeding the company's own guided range of 17–19%. The primary engine behind the quarter was an explosive performance in the Cardiovascular segment, which surged 26.2% on a reported basis, led by Cardiology growing nearly 30% as the FARAPULSE pulsed field ablation platform continued to gain traction, including positive 12-month clinical data from the ADVANTAGE AF trial supporting the system's safety and efficacy in persistent atrial fibrillation. Management raised its full-year reported sales growth guidance to 15–17%, even as it absorbed an anticipated $200 million tariff headwind, projecting adjusted EPS of $2.87 to $2.94 for the year; second-quarter adjusted EPS guidance of $0.71 to $0.73 suggests continued momentum heading into the summer.

Key Takeaways
  • Cardiovascular segment organic growth of 25.6%, led by Cardiology at 31.2% organic growth
  • U.S. market growth of 31.1% driven by strong adoption of cardiac and interventional technologies
  • Strong product portfolio execution across all business units
  • Meaningful innovation and clinical science driving category leadership

“We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio.”

Boston Scientific CEO, on the earnings call

Forward Guidance & Outlook

For full year 2025, Boston Scientific estimates reported net sales growth of approximately 15–17% and organic net sales growth of 12–14%. Full year GAAP EPS is estimated at $1.86 to $1.93, and adjusted EPS at $2.87 to $2.94. For Q2 2025, the company expects reported net sales growth of 17.5–19.5% and organic growth of 13–15%, with GAAP EPS of $0.45 to $0.47 and adjusted EPS of $0.71 to $0.73.

BSX YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$0$2.0B$4.0B$3.9B$4.7BRevenue$2.4B$3.2BGross Profit$644.0M$921.0MOperating Income$494.0M$674.0MNet Income
$0$2.0B$4.0BRevenueGross ProfitOperating IncomeNet Income

BSX Revenue by Segment

Cardiovascular$3.1B+26.2%
Cardiology$2.4B+29.8%
MedSurg$1.6B+11.7%
Endoscopy$673.0M+4.7%
Urology$633.0M+23.5%
Peripheral Interventions$656.0M+14.4%
Neuromodulation$271.0M+5.8%

BSX Revenue by Geography

United States$3.0B+31.1%
EMEA$846.0M+5.5%
Asia Pacific$701.0M+8.2%
Latin America$155.0M+4.4%

Figures from SEC filings and company reports. Not investment advice.